195 related articles for article (PubMed ID: 20095867)
1. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities.
Weinreb O; Amit T; Mandel S; Kupershmidt L; Youdim MB
Antioxid Redox Signal; 2010 Sep; 13(6):919-49. PubMed ID: 20095867
[TBL] [Abstract][Full Text] [Related]
2. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway.
Weinreb O; Amit T; Mandel S; Youdim MB
Neurodegener Dis; 2012; 10(1-4):112-5. PubMed ID: 22156453
[TBL] [Abstract][Full Text] [Related]
3. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of hypoxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF- and CREB-independent pathways.
Siddiq A; Aminova LR; Troy CM; Suh K; Messer Z; Semenza GL; Ratan RR
J Neurosci; 2009 Jul; 29(27):8828-38. PubMed ID: 19587290
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway.
Mandel SA; Avramovich-Tirosh Y; Reznichenko L; Zheng H; Weinreb O; Amit T; Youdim MB
Neurosignals; 2005; 14(1-2):46-60. PubMed ID: 15956814
[TBL] [Abstract][Full Text] [Related]
6. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia inducible factor-1 as a target for neurodegenerative diseases.
Zhang Z; Yan J; Chang Y; ShiDu Yan S; Shi H
Curr Med Chem; 2011; 18(28):4335-43. PubMed ID: 21861815
[TBL] [Abstract][Full Text] [Related]
8. Local delivery of iron chelators reduces in vivo remodeling of a calcium phosphate bone graft substitute.
Drager J; Sheikh Z; Zhang YL; Harvey EJ; Barralet JE
Acta Biomater; 2016 Sep; 42():411-419. PubMed ID: 27449336
[TBL] [Abstract][Full Text] [Related]
9. Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities.
Merelli A; RodrÃguez JCG; Folch J; Regueiro MR; Camins A; Lazarowski A
Curr Neuropharmacol; 2018; 16(10):1484-1498. PubMed ID: 29318974
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke.
Speer RE; Karuppagounder SS; Basso M; Sleiman SF; Kumar A; Brand D; Smirnova N; Gazaryan I; Khim SJ; Ratan RR
Free Radic Biol Med; 2013 Sep; 62():26-36. PubMed ID: 23376032
[TBL] [Abstract][Full Text] [Related]
11. Membrane permeability of redox active metal chelators: an important element in reducing hydroxyl radical induced NAD+ depletion in neuronal cells.
Jayasena T; Grant RS; Keerthisinghe N; Solaja I; Smythe GA
Neurosci Res; 2007 Mar; 57(3):454-61. PubMed ID: 17210195
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation and neuroprotection in neurodegenerative diseases.
Li X; Jankovic J; Le W
J Neural Transm (Vienna); 2011 Mar; 118(3):473-7. PubMed ID: 21161300
[TBL] [Abstract][Full Text] [Related]
13. The role of iron in cell cycle progression and the proliferation of neoplastic cells.
Le NT; Richardson DR
Biochim Biophys Acta; 2002 Oct; 1603(1):31-46. PubMed ID: 12242109
[TBL] [Abstract][Full Text] [Related]
14. Hinokitiol activates the hypoxia-inducible factor (HIF) pathway through inhibition of HIF hydroxylases.
Lee MJ; Kim JW; Yang EG
Biochem Biophys Res Commun; 2010 May; 396(2):370-5. PubMed ID: 20416277
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease.
Gaeta A; Molina-Holgado F; Kong XL; Salvage S; Fakih S; Francis PT; Williams RJ; Hider RC
Bioorg Med Chem; 2011 Feb; 19(3):1285-97. PubMed ID: 21236688
[TBL] [Abstract][Full Text] [Related]
17. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
Whitnall M; Richardson DR
Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration?
Correia SC; Moreira PI
J Neurochem; 2010 Jan; 112(1):1-12. PubMed ID: 19845827
[TBL] [Abstract][Full Text] [Related]
19. Neurodegenerative diseases and therapeutic strategies using iron chelators.
Ward RJ; Dexter DT; Crichton RR
J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
[TBL] [Abstract][Full Text] [Related]
20. Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins.
Srinivas V; Zhang LP; Zhu XH; Caro J
Biochem Biophys Res Commun; 1999 Jul; 260(2):557-61. PubMed ID: 10403805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
